Hepatocyte growth factor (HGF) binding antibody

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S387100, C530S388100, C530S388150

Reexamination Certificate

active

07659378

ABSTRACT:
The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.

REFERENCES:
patent: 5707624 (1998-01-01), Nickoloff et al.
patent: 5766886 (1998-06-01), Studnicka et al.
patent: 5997868 (1999-12-01), Goldberg et al.
patent: 6432406 (2002-08-01), Goldberg et al.
patent: 6881557 (2005-04-01), Foote
patent: 7220410 (2007-05-01), Kim et al.
patent: 2008/0038256 (2008-02-01), Chung et al.
patent: 2008/0108565 (2008-05-01), Winston et al.
patent: WO-01/34650 (2001-05-01), None
patent: WO-2005/017107 (2005-02-01), None
patent: WO-2005/044848 (2005-05-01), None
patent: WO-2005/107800 (2005-11-01), None
patent: WO-2006/130773 (2006-12-01), None
patent: WO-2007/115049 (2007-10-01), None
Burgess et al. “Fully Human Monoclonal Antibodies to Hepatocyte Growth Factor With Therapeutic Potential Against Hepatocyte Growth Factor/C-Met-Dependent Human Tumors” (2006) Cancer Res. 66:3, pp. 1721-1729.
Burr et al. “Anti-Hepatocyte Growth Factor Antibody Inhibits Hepatocyte Proliferation During Liver Regeneration” Journal of Pathology, Chicester, Sussex, GB, vol. 185, (Jul. 1998) pp. 298-302.
Cao et al. “Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models” Proc. Natl. Acad. Sci. 2001 USA 98: 7443-7448.
Hwang et al. “Use of human germline genes in a CDR homology-based approach to antibody humanization” Methods. May 2005;36(1):35-42.
Kim et al. “Systemic anti-hepatocyte growth factor monoclonal antibody thereapy induces the regression of intracranial glioma axenografts” (2006) Clinical Cancer Research 12: 1292-1298.
R&D Systems, Inc. 1999 Catalog, p. 185, Cat. #MAB294, anti-human HGF monoclonal antibody.
Rubin et al. “Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product” Biochim Biophys Acta. Dec. 23, 1993;1155(3):357-71.
Studnicka et al. “Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues” Protein Eng. Jun. 1994;7(6):805-14.
Tan et al. ““Superhumanized” antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28” J Immunol. Jul. 15, 2002;169(2):1119-25.
Zaccolo et al. “Dimerization of FAB Fragments Enables Ready Screening of Phage Antibodies that Affect Hepatocyte Growth Factor/Scatter Factor Activity on Target Cells” European Journal of Immunology, vol. 27, No. 3, (1997), pp. 618-623.
International Search Report for PCT/2007/012950 dated Apr. 15, 2008.
International Search Report for PCT/2007/012939 dated Jan. 30, 2008.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Hepatocyte growth factor (HGF) binding antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hepatocyte growth factor (HGF) binding antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatocyte growth factor (HGF) binding antibody will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4184070

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.